MK-1088: Discovery Data for a Dual-Antagonist Cancer Immunotherapy Drug

figshare hosts a dataset describing the discovery and optimization of MK-1088, a potent dual A2A/A2B adenosine receptor antagonist. Yonglian Zhang authored this publication, which was last updated on 2026-05-05. The dataset likely contains experimental results or compound properties supporting the progression of MK-1088 to human clinical studies.

Use Cases

• Train models to predict drug efficacy based on receptor antagonism data mentioned in the description
• Analyze compound optimization pathways for dual-target inhibitors
• Benchmark new adenosine receptor antagonists against the potency and selectivity metrics described

Strengths

• The dataset is associated with a compound (MK-1088) identified for progression to human clinical studies
• The description provides a clear biological rationale for dual A2A/A2B receptor blockade in cancer immunotherapy

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is 3.5 KB, indicating a very limited scope

Provenance

Source

figshare

Freshness

Last updated 2026-05-05 14:36:02; freshness should be verified